Drug Trial Radar · NCT06170788
Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab Versus Pembrolizumab Alone in Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥ 50% (MK-2870-007)
Last checked: Nov 19, 2026Latest source record: Nov 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
614
Planned (sponsor's estimate)
Start
Dec 15, 2023
Primary completion
Jan 25, 2028
Study completion May 27, 2030
Sponsor
- Lead sponsor
- Merck Sharp & Dohme LLCMerck & Co. (MRK)
- Sponsor type
- Industry
- First posted
- Dec 14, 2023
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Single (outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The primary objective of the study is to compare sacituzumab tirumotecan combined with pembrolizumab to pembrolizumab alone with respect to overall survival (OS). The primary hypothesis is that the combination of sacituzumab tirumotecan and pembrolizumab is superior to pembrolizumab alone with respect to OS.
Conditions
- Non-small Cell Lung Cancer (NSCLC)
Interventions
Sacituzumab tirumotecanBiological
IV infusion
PembrolizumabBiological
IV infusion
Supportive care measuresDrug
Participants are allowed to take supportive care measures at the discretion of the investigator. Prophylactic supportive care measures may include but are not limited to antiemetic agents, antidiarrheal agents, granulocyte and erythroid growth factors, and blood transfusions
Primary outcomes
What the sponsor says the trial is designed to measure.
- Overall Survival (OS)Time frame: Up to approximately 49 months
Locations
220 sites in 26 countries. Site status is shown where the registry gives one.
Mayo Clinic in Arizona - Phoenix ( Site 0147)
Phoenix, Arizona · Recruiting
Roy and Patricia Disney Family Cancer Center - Providence Saint Joseph Medical Center ( Site 0130)
Burbank, California · Recruiting
Cancer Centers of Colorado St. Mary's Regional Hospital ( Site 0132)
Grand Junction, Colorado · Recruiting
Mayo Clinic in Florida-Mayo Clinic Comprehensive Cancer Center ( Site 0133)
Jacksonville, Florida · Recruiting
Northwest Georgia Oncology Centers, a Service of Wellstar Cobb Hospital-Research ( Site 0106)
Marietta, Georgia · Completed
The University of Louisville, James Graham Brown Cancer Center ( Site 0121)
Louisville, Kentucky · Completed
New England Cancer Specialists ( Site 0143)
Westbrook, Maine · Recruiting
University of Massachusetts Chan Medical School-Division of Hematology/Oncology ( Site 0144)
Worcester, Massachusetts · Completed
Allina Health Cancer Institute - Abbott Northwestern Hospital ( Site 0115)
Minneapolis, Minnesota · Recruiting
Mayo Clinic - Rochester ( Site 0148)
Rochester, Minnesota · Recruiting
Hattiesburg Clinic Hematology/Oncology ( Site 0104)
Hattiesburg, Mississippi · Recruiting
Renown Regional Medical Center-Renown Health Medical Oncology ( Site 0134)
Reno, Nevada · Recruiting
University Hospitals Cleveland Medical Center ( Site 0119)
Cleveland, Ohio · Completed
Good Samaritan Regional Medical Center-Samaritan Pastega Regional Cancer Center ( Site 0117)
Corvallis, Oregon · Recruiting
Oncology Consultants P.A. ( Site 0129)
Houston, Texas · Completed
Hospital Aleman-Oncology ( Site 0300)
Buenos Aires, Argentina · Recruiting
Instituto Alexander Fleming ( Site 0306)
Ciudad Autónoma de Buenos Aires, Buenos Aires, Argentina · Recruiting
Hospital Británico de Buenos Aires-Oncology ( Site 0304)
Buenos Aires, Buenos Aires F.D., Argentina · Recruiting
Centro Privado de RMI Río Cuarto S.A. II ( Site 0310)
Río Cuarto, Córdoba Province, Argentina · Recruiting
Instituto de Oncología de Rosario ( Site 0301)
Rosario, Santa Fe Province, Argentina · Recruiting
Port Macquarie - Mid North Coast Cancer Institute-Medical Oncology ( Site 3002)
Port Macquarie, New South Wales, Australia · Recruiting
Westmead Hospital ( Site 3000)
Westmead, New South Wales, Australia · Recruiting
Grampians Health-Medical Oncology ( Site 3001)
Ballarat Central, Victoria, Australia · Completed
Northern Hospital ( Site 3003)
Epping, Victoria, Australia · Recruiting
Peninsula University Hospital ( Site 3004)
Frankston, Victoria, Australia · Recruiting
Instituto Nacional de Câncer - INCA ( Site 0405)
Rio de Janeiro, Brazil · Recruiting
Núcleo de Pesquisa Clínica da Rede São Camilo ( Site 0401)
São Paulo, Brazil · Recruiting
Irmandade da Santa Casa de Misericórdia de Porto Alegre ( Site 0409)
Porto Alegre, Rio Grande do Sul, Brazil · Recruiting
Clinica Viver ( Site 0400)
Santa Maria, Rio Grande do Sul, Brazil · Active not recruiting
Fundação Pio XII - Hospital de Câncer de Barretos ( Site 0402)
Barretos, São Paulo, Brazil · Recruiting
Fundação Faculdade Regional de Medicina de São José do Rio Preto ( Site 0406)
São José do Rio Preto, São Paulo, Brazil · Recruiting
William Osler Health System ( Site 0203)
Brampton, Ontario, Canada · Recruiting
Trillium Health Partners - Credit Valley Hospital ( Site 0202)
Mississauga, Ontario, Canada · Recruiting
McGill University Health Centre ( Site 0200)
Montreal, Quebec, Canada · Completed
Bradford Hill Norte ( Site 0516)
Antofagasta, Chile · Recruiting
Clinica Universidad Catolica del Maule-Oncology ( Site 0501)
Talca, Maule Region, Chile · Recruiting
Orlandi Oncologia-Oncology ( Site 0504)
Santiago, Region M. de Santiago, Chile · Recruiting
FALP-UIDO ( Site 0509)
Santiago, Region M. de Santiago, Chile · Recruiting
Bradfordhill-Clinical Area ( Site 0507)
Santiago, Region M. de Santiago, Chile · Recruiting
Second Affiliated hospital of Anhui Medical University ( Site 3133)
Hefei, Anhui, China · Completed
Showing 40 of 220 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.